Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
13.00
-1.66 (-11.32%)
At close: Oct 6, 2026, 4:00 PM EDT
13.33
+0.33 (2.54%)
After-hours: Oct 6, 2026, 7:56 PM EDT
Arcturus Therapeutics Holdings Employees
As of December 31, 2025, Arcturus Therapeutics Holdings had 111 total employees, including 106 full-time and 5 part-time employees. The number of employees decreased by 65 or -36.93% compared to the previous year.
Employees
111
Change (1Y)
-65
Growth (1Y)
-36.93%
Revenue / Employee
$264,577
Profits / Employee
-$840,324
Market Cap
369.50M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 111 | -65 | -36.93% | 106 | 5 |
| Dec 31, 2024 | 176 | -4 | -2.22% | 174 | 2 |
| Dec 31, 2023 | 180 | 10 | 5.88% | 180 | 0 |
| Dec 31, 2022 | 170 | -7 | -3.95% | 170 | 0 |
| Dec 31, 2021 | 177 | 59 | 50.00% | 177 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Capricor Therapeutics | 231 |
| ARS Pharmaceuticals | 200 |
| Kyverna Therapeutics | 149 |
| Editas Medicine | 87 |
| Prothena Corporation | 67 |
| AgomAb Therapeutics NV | 62 |
| Tectonic Therapeutic | 60 |
| Atea Pharmaceuticals | 55 |
ARCT News
- 12 days ago - Arcturus Therapeutics price target lowered to $20 from $23 at BTIG - TheFly
- 12 days ago - Arcturus Therapeutics upgraded to Buy from Neutral at Citi - TheFly
- 12 days ago - Arcturus Therapeutics upgraded to Buy from Neutral at Citi - TheFly
- 13 days ago - Arcturus Therapeutics Holdings Transcript: Status update - Transcripts
- 13 days ago - Arcturus Therapeutics Holdings Press release: Status update - Filings
- 13 days ago - Arcturus Therapeutics Holdings Slides: Status update - Filings
- 13 days ago - Arcturus Therapeutics announces interim OTC deficiency Phase 2 results - TheFly
- 13 days ago - Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform - Business Wire